Cancer Risk Management Practices of Noncarriers Within BRCA1/2 Mutation–Positive Families in the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer

Women from BRCA mutation-positive families who do not carry the family-specific mutation are generally at average cancer risk and therefore do not require intensive risk management. Participants were female noncarriers from BRCA mutation-positive families who had responded to 3 yearly follow-up ques...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2008-01, Vol.26 (2), p.225-232
Hauptverfasser: DAWSON, Sarah-Jane, PRICE, Melanie A, PHILLIPS, Kelly-Anne, JENKINS, Mark A, MCKINLEY, Joanne M, BUTOW, Phyllis N, MCLACHLAN, Sue-Anne, LINDEMAN, Geoffrey J, WEIDEMAN, Prue, FRIEDLANDER, Michael L, HOPPER, John L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Women from BRCA mutation-positive families who do not carry the family-specific mutation are generally at average cancer risk and therefore do not require intensive risk management. Participants were female noncarriers from BRCA mutation-positive families who had responded to 3 yearly follow-up questionnaires and had chosen to either receive or not receive their genetic test result. In the former group, undertaking mammography younger than age 40 years or more than once every 2 years, clinical breast examination (CBE) more than yearly, breast self-examination (BSE) more than monthly, or any transvaginal ultrasound (TVU) or CA-125 was considered overscreening. Screening behaviors of women who did and did not know their genetic test result were compared. Logistic regression and nonparametric analyses were performed to identify demographic and psychosocial factors (respectively) associated with overscreening. Of 325 eligible women, 116 knew their mutation status and 209 did not. For the first group, proportions overscreening were mammography, 53%; CBE, 10%; BSE, 11%; TVU, 7%; and CA-125, 10%. There were no significant differences in screening behaviors between the groups. In those aware of their mutation status, parous women were more likely to overuse mammography (odds ratio [OR] = 4.4; 95% CI, 1.1 to 17; P = .03) and women with one or more first-degree relative with ovarian cancer (OC) were more likely to overuse OC screening (TVU: OR = 6.00; 95% CI, 1.0 to 35.1; P = .047, and CA-125: OR = 6.50; 95% CI, 1.49 to 28.4; P = .013). The reasons for overuse of screening (particularly mammography) by mutation noncarriers require additional elucidation given the potential for harm.
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2007.11.0262